In this regard, it has been suggested that activation of PPARγ during COVID-19 can reduce the circulating levels of TNF-α, IL-1, and IL-6 in the innate immune cells such as macrophages and monocytes through interaction with NF-κB (169). The gene discussed is IL6; the disease is COVID-19.